EARLY TO THE PARTY

[TPX]

$MCET HUGE PATENTS AND PARTNERS!!!

MultiCell Technologies MCT-465 MCT 475 MCT-485!

(MCET) Mentioned - 3DNA Nanotechnology Platform Provider, Genisphere, Closes $2 Million in Private Funding

Published on September 17, 2014 at 4:16 AM

Genisphere LLC, provider of the 3DNA® nanotechnology platform, reported today it has closed $2 million in private funding from existing investors, including Corporate Fuel Partners, a New York fund. This round of fundraising will accelerate Genisphere's targeted drug delivery initiative, following key milestones including the company's demonstration of cell-specific (cytosolic and nuclear) delivery of drugs with functional intracellular effects without apparent toxicity.

"3DNA nanotechnology is a versatile and unique delivery platform with potentially diverse and enormously important medical applications,” noted Vladimir Muzykantov, MD, PhD, Director of the Center for Targeted Therapeutics and Translational Nanomedicine (CT3N) at the University of Pennsylvania.

“Genisphere has created an impressive portfolio of joint projects to identify the most promising leads and expand the evolving practical applications beyond the initial prototypes,” he added. “Genisphere’s corporate membership in CT3N offers it direct access to leading experts in the field; indeed, University of Pennsylvania counterparts have been intrigued by delivery opportunities provided by 3DNA technology.”

Genisphere established these key collaborations to generate preclinical data showing the versatility and efficacy of the 3DNA platform in targeted delivery of small drugs, biologics, and nucleic acids. Last year, Genisphere announced its first research collaboration agreement with MultiCell Technologies, Inc. (OTC: MCET), which is investigating the use of the 3DNA platform to help facilitate the targeted delivery of their lead drug candidate, MCT485, for the treatment of primary hepatocellular carcinoma. The number of collaborations has now grown to more than 25 and includes several projects with large pharmaceutical companies.

"Pre-clinical data have demonstrated specific targeting of tumors, selective killing of targeted cells, tumor shrinkage, and no observed toxicity," said Bob Getts, Genisphere’s Chief Science Officer. According to Getts, key milestones achieved included excellent biodistribution profiles, transport across the blood-brain barrier, and specific accumulation in targeted tumors.

Getts also pointed out the flexibility of the 3DNA platform to deliver hundreds of tracking labels to targeted tissues, providing pharma companies with an option to incorporate a companion diagnostic into the drug development process. He summarized, "This round of funding will accelerate our joint efforts with our current collaborators, and gives Genisphere the resources to support additional partnerships."

Genisphere also plans to advance its own lead oncology compounds based on the 3DNA drug delivery platform.

Source: http://genisphere.com/

MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer

WOONSOCKET, R.I., Aug. 25, 2014 /PRNewswire via COMTEX/ -- MultiCell Technologies, Inc. (OTC: MCET) has been issued U.S. patent 8,809,290 covering novel drug compositions and platform technologies which redirect the immune system response to protect against highly virulent virus infection and cancer. These novel drug compositions consisting of noncoding doubled stranded RNA (dsRNA) molecules and recombinant immunoglobulin-peptide (IgP) molecules demonstrate unique immune stimulating activity, and the ability to present peptide antigens to immune cells resulting in protective anti-tumoral and anti-viral immunity.

In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal's immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity. Tumor rejection and protection against similar and new tumor variants was found to also be associated with specific, overall expansion of cytokine producing cells. This finding indicates a broadening of the repertoire of anti-tumor immune cells and the development of immune memory in the animal.

Mice immunized with MCT-465 and MCT-475 resulted in the priming of an immune response capable of limiting the replication of virus subsequent to further virus infectious challenge. During viral infection, specific immune system cells begin to proliferate and differentiate which defines the adaptive immune response to the infection. In mouse models, administration of MCT-465 and MCT-475 greatly enhanced the generation of interferon gamma (IFN) and interleukin-2 (IL-2) producing virus antigen-specific T-cells resulting in significantly reduced virus levels present in the animal.

MultiCell is developing MCT-465 and MCT-475 for the treatment of hepatitis B virus infection and hepatitis C virus infection, and for the treatment of certain cancers.

Chronic hepatitis B and chronic hepatitis C virus infection are recognized as major factors worldwide that increase the risk of hepatocellular carcinoma. According to the U.S. National Cancer Institute (NCI), chronic hepatitis B virus infection and chronic hepatitis C virus infection account for about 30% to 40% of all reported USA cases of hepatocellular carcinoma.

Treatment of hepatocellular carcinoma, the most common form of primary liver cancer, represents a major unmet medical need. Hepatocellular carcinoma is a leading cause of cancer death worldwide, and is the fourth most common cancer in the world. Over 1 million cases of hepatocellular carcinoma are reported annually worldwide. Current approaches for treatment of hepatocellular carcinoma are of limited efficacy. According to the NCI, only 16% of patients diagnosed with primary liver cancer survive longer than 5 years.

MultiCell is also developing MCT-485, a very small dsRNA therapeutic, thought to target cancer by delivering a cytotoxic effect to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells. MCT-485 appears to have no effect on cells not directly involved in the process of relapse, progression and metastasis of cancer. MCT-485 appears to exert a preferential biological activity on liver cancer cells while showing no effect on normal liver cells.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools for the treatment of primary multiple sclerosis-related fatigue and cancer. For more information about MultiCell Technologies, please visit http://www.multicelltech.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". MultiCell bases these forward- looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents that MultiCell files with the Securities and Exchange Commission, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2013, and all of MultiCell's quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

SOURCE MultiCell Technologies, Inc.

http://www.otcmarkets.com/stock/MCET/news

Multicell Technologies awarded patent for cancer, hepatitis fighting platform

9/3/14

WOONSOCKET – MultiCell Technologies Inc. has been issued a U.S. patent for drug compositions and platform technologies, which are designed treat virus infections and cancer.

The patent seeks to address what the company calls an unmet medical need. The therapeutics will be used to treat hepatitis B and hepatitis C, as well as hepatocellular carcinoma, which is one of the leading causes of cancer deaths worldwide and the fourth most common form of liver cancer. According to the National Cancer Institute, there are more than 1 million cases of hepatocellular carcinoma worldwide and only 16 percent of patients diagnosed with primary liver cancer live longer than five years.

After studying mouse cancer models, MultiCell Technologies found that a combination of MCT-465, a noncoding doubled-stranded RNA therapeutic and MCT-475, a recombinant immunoglobulin-peptide therapeutic, were able to stimulate the animal’s immune system to eradicate an engrafted tumor. The drug combination also promoted a protective immunity toward any new tumor variants by producing more cytokine proteins (interferon gamma and interleukin-2). The proteins produced antigen-specific T cells, leaving immunized mice with significantly lower virus levels than those that weren’t.

Aside from finding new anti-tumor immune cells, findings also provided insight about the immune memory in animals.

MultiCell Technologies Inc. is a clinical-stage biopharmaceutical company based in Woonsocket that develops novel therapeutics and discovery tools in order to treat neurological disorders, hepatic disease and cancer.

http://pbn.com/multicell,99698?print=1

MULTICELL TECHNOLOGIES PUBLISHED PATENT: US PATENT 8,809,290

United States Patent 8,809,290
Assignee: Multicell Immunotherapeutics, Inc. (Woonsocket, RI)
Bot, et al. August 19, 2014

Methods and compositions to generate and control the effector profile of T cells by simultaneous loading and activation of selected subsets of antigen presenting cells

Abstract

The present invention is directed to novel compositions that cause effective redirection of class I-immunity to Tc1 effectors, that take advantage of the unexpected loading of MHC I by peptide within IgG backbone combined with appropriate instruction of antigen presenting cells. Such compositions are able to transform a seemingly ineffective therapeutics into a highly effective one, associated with generation of class I-restricted cytolytic cells and IFN-.gamma., IL-2 producing T cells, further associated with protection against a highly virulent microbe or recovery from malignant tumoral process.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8809290.PN.&OS=PN/8809290&RS=PN/8809290

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

http://www.multicelltech.com/therapeutic-pipeline/published-patents/

Partners

AMARIN
CORNING
PFIZER

http://www.multicelltech.com/about-us/partners/

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc.

US Patent 6,737,057: Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US Patent 6,129,911: Liver stem cell
US Patent 6,872,389: Liver stem cell
US Patent 6,017,760: Isolation and culture of porcine hepatocytes
US Patent 6,107,043: Immortalized hepatocytes
US Patent 5,043,260: Perfusion device with hepatocytes
US Patent 4,795,459: Implantable Prosthetic Device (endothelial)
US Patent 6,858,146: Artificial Liver Apparatus and Method (Trademarked as the SybiolR synthetic bio-liver)
US Patent 7,935,528 The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.
US Patent 7,566,567: Immortalized hepatocytes
US20070104696A1: Use of cell lines to produce active therapeutic proteins
US20070004039A1: Immortalized hepatocytes
EP1704227B1: IMMORTALIZED HEPATOCYTES
DE602004025380C0: IMMORTALISIERTE HEPATOZYTEN
AT0456376E: IMMORTALISIERTE HEPATOZYTEN
AU8229981A1: Immortalized hepatocytes
AU4322811AH: Immortalized hepatocytes
EP1704227A4: IMMORTALIZED HEPATOCYTES
WO06041488C1: IMMORTALIZED HEPATOCYTES
WO06041488A1: IMMORTALIZED HEPATOCYTES
IL0174787A0: Use of cell lines to produce active therapeutic proteins
EP1685252A4: Use of cell lines to produce active therapeutic proteins
EP1704227A1: IMMORTALIZED HEPATOCYTES
EP1685252A2: Use of cell lines to produce active therapeutic proteins
CA2550452A1 IMMORTALIZED HEPATOCYTES
AU4322811A1 Immortalized hepatocytes
WO05034876A3 Use of cell lines to produce active therapeutic proteins
WO05034876A2 Use of cell lines to produce active therapeutic proteins
CA2541380A1 Use of cell lines to produce active therapeutic proteins
AU4280238AB Use of cell lines to produce active therapeutic proteins
AU4280238A1 Use of cell lines to produce active therapeutic proteins
Xenogenics.

When Xenogenics acquired the assets of Bioabsorbable Therapeutics, Inc., it acquired and continues to support issued U.S. patent 7,674,285: Polyanhydride polymers and their uses in biomedical devices. This process is incorporated in and trademarked as the Ideal Bio-StentR.

MultiCell ImmunoTherapeutics.

Below is a listing of the intellectual properties of which Astral, Inc. is the Assignee. This intellectual property is now owned by MultiCell Immunotherapeutics resulting from the purchase agreement between MultiCell Technologies, Inc. and Alliance Pharmaceuticals, Inc.


US20120189645A1:Compositions and methods to treat and control tumors.
CN100376594C: Double-chain RNA and method to initiate, enhance or adjust immunomodulatory or immune response.
CN1795274A: Selected RNA motifs to include cell death and/or apoptosis.
CN1780848A: Compositions and methods to initiate or enhance antibody and
major-histocompatibility class i or class ii-restricted t cell responses by
using immunomodulatory, non-coding RNA motifs.
WO04087877A3: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
CN1703427A: Methods and compositions to generate and control the effector profile of Tcells by simultaneous loading and activation of selected subsets of antigen presenting cells .
WO04087877A2: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
WO04027049B1: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO04027049A3: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO03078595B1: IMMUNOSTIMULATORY DOUBLE STRANDED RNA AND METHODS OF INDUCING, ENHANCING OR MODULATING THE IMMUNE RESPONSE.
WO04027049A2: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO03078595A3: IMMUNOSTIMULATORY DOUBLE STRANDED RNA AND METHODS OF INDUCING, ENHANCING OR MODULATING THE IMMUNE RESPONSE.
CA2520181A1: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
CA2499066A1: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
AU4225480A1: Selected RNA motifs to include cell death and/or apoptosis.
AU3276932A1: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO03078595A2: COMPOSITIONS AND METHODS TO INITIATE OR ENHANCE ANTIBODY AND MAJOR-HISTOCOMPATIBILITY CLASS I OR CLASS II-RESTRICTED T CELL RESPONSES BY
USING IMMUNOMODULATORY, NON-CODING RNA MOTIFS.
CA2479187A1: IMMUNOSTIMULATORY DOUBLE STRANDED RNA AND METHODS OF INDUCING, ENHANCING OR MODULATING THE IMMUNE RESPONSE.
AU3218181A1: COMPOSITIONS AND METHODS TO INITIATE OR ENHANCE ANTIBODY AND MAJOR-HISTOCOMPATIBILITY CLASS I OR CLASS II-RESTRICTED T CELL RESPONSES BY USING IMMUNOMODULATORY, NON-CODING RNA MOTIFS.
US7566567: Immortalized hepatocytes
US20070104696A1: Use of cell lines to produce active therapeutic proteins
US20070004039A1: Immortalized hepatocytes
EP1704227B1:
IMMORTALIZED HEPATOCYTES
DE602004025380C0: IMMORTALISIERTE HEPATOZYTEN
AT0456376E: IMMORTALISIERTE HEPATOZYTEN
AU8229981A1: Immortalized hepatocytes
AU4322811AH: Immortalized hepatocytes
EP1704227A4: IMMORTALIZED HEPATOCYTES
WO06041488C1: IMMORTALIZED HEPATOCYTES
WO06041488A1: IMMORTALIZED HEPATOCYTES
IL0174787A0: Use of cell lines to produce active therapeutic proteins
EP1685252A4: Use of cell lines to produce active therapeutic proteins
EP1704227A1: IMMORTALIZED HEPATOCYTES
EP1685252A2: Use of cell lines to produce active therapeutic proteins
CA2550452A1 IMMORTALIZED HEPATOCYTES
AU4322811A1 Immortalized hepatocytes
WO05034876A3 Use of cell lines to produce active therapeutic proteins
WO05034876A2 Use of cell lines to produce active therapeutic proteins
CA2541380A1 Use of cell lines to produce active therapeutic proteins
AU4280238AB Use of cell lines to produce active therapeutic proteins
AU4280238A1 Use of cell lines to produce active therapeutic proteins

http://www.multicelltech.com/therapeutic-pipeline/published-patents/